Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $59.0700 on 2018-01-18

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical
106
Abbott Labs (ABT-N)

Last Price Recorded: $59.0700 on 2018-01-18

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert
PAST TOP PICK
Abbott Labs(ABT-N) 

May 9, 2013

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out.  This is about the best performing part of the market this year.  Good dividend growth and very strong balance sheets. 

biotechnology/pharmaceutical

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out.  This is about the best performing part of the market this year.  Good dividend growth and very strong balance sheets. 

biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Ma...

PricePrice
$36.180
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

April 15, 2013

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.

biotechnology/pharmaceutical

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.

biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs...

PricePrice
$36.130
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

April 9, 2013

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.

biotechnology/pharmaceutical

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$36.660
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

March 7, 2013

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.

biotechnology/pharmaceutical

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.

biotechnology/pharmaceutical
Patrick Horan

Portfolio Manager, Agilith Capital Inc...

PricePrice
$34.430
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

February 26, 2013

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.

biotechnology/pharmaceutical

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Manage...

PricePrice
$34.060
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

February 25, 2013

She sold ABv.  But ABT-N has a very good basic business.  Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon. 

biotechnology/pharmaceutical

She sold ABv.  But ABT-N has a very good basic business.  Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon. 

biotechnology/pharmaceutical
Chyanne Fickes

Vice President of Investments, Stone Funds...

PricePrice
$34.270
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

February 12, 2013

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.

biotechnology/pharmaceutical

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$34.300
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

February 5, 2013

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.

biotechnology/pharmaceutical

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.

biotechnology/pharmaceutical
John O'Connell, CFA

Chairman and CEO, Davis Rea...

PricePrice
$33.840
Owned Owned
Unknown

HOLD
Abbott Labs(ABT-N) 

January 10, 2013

Had a spinoff of their pharmaceutical side and this company now just represents the diagnostic and nutritional business. If you own, wait and see how things settle out for them.

biotechnology/pharmaceutical

Had a spinoff of their pharmaceutical side and this company now just represents the diagnostic and nutritional business. If you own, wait and see how things settle out for them.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$33.850
Owned Owned
No

BUY
Abbott Labs(ABT-N) 

December 3, 2012

It already had a bump up in price, but he is planning on holding both parts.  Buying for new clients.

biotechnology/pharmaceutical

It already had a bump up in price, but he is planning on holding both parts.  Buying for new clients.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Manage...

PricePrice
$64.290
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

November 30, 2012

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 

biotechnology/pharmaceutical

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 

biotechnology/pharmaceutical
Chyanne Fickes

Vice President of Investments, Stone Funds...

PricePrice
$65.000
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

November 26, 2012

You can buy at its model price and when the company splits up it would increase value.  The balance sheet has high growth parts buried within it.  These smaller parts create more value.  The pieces are worth more than the whole.  40 increases in dividends and very shareholder friendly.  He would stay with both after the split until you can review balance sheets.

biotechnology/pharmaceutical

You can buy at its model price and when the company splits up it would increase value.  The balance sheet has high growth parts buried within it.  These smaller parts create more value.  The pieces are worth more than the whole.  40 increases in dividends and very shareholder friendly.  He would stay with both after the split until you can review balance sheets.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc....

PricePrice
$64.360
Owned Owned
Yes

SELL
Abbott Labs(ABT-N) 

November 21, 2012

(Market Call Minute) Would sell on the split.  It is too complicated to be there with the split.

biotechnology/pharmaceutical

(Market Call Minute) Would sell on the split.  It is too complicated to be there with the split.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$63.330
Owned Owned
Unknown

TOP PICK
Abbott Labs(ABT-N) 

November 19, 2012

12 drugs under patent after a current one comes off patent.  A hepatitis drug is about to come out as well.  It could hit its 52 week high.

biotechnology/pharmaceutical

12 drugs under patent after a current one comes off patent.  A hepatitis drug is about to come out as well.  It could hit its 52 week high.

biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Manageme...

PricePrice
$62.920
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

November 12, 2012

(Market Call Minute) Sell off is because it is going to split itself up which will realize value.

biotechnology/pharmaceutical

(Market Call Minute) Sell off is because it is going to split itself up which will realize value.

biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs...

PricePrice
$64.870
Owned Owned
Yes

Showing 46 to 60 of 106 entries
<< < 2 3 4 5 6 > >>

No Comments.


You must be logged in to comment.

Successfully Saved Company